"The National Institute of Allergy and Infectious Diseases (NIAID) has released updated guidelines for peanut allergy prevention, with specific strategies for infants at various levels of risk. The evidence-based recommendations highlight data fro"...
In controlled clinical studies of EMADINE (emedastine difumarate ophthalmic solution ) lasting for 42 days, the most frequent adverse reaction was headache (11%). The following adverse experiences were reported in less than 5% of patients: Abnormal dreams, asthenia, bad taste, blurred vision, burning or stinging, corneal infiltrates, corneal staining, dermatitis, discomfort, dry eye, foreign body sensation, hyperemia, keratitis, pruritus, rhinitis, sinusitis, and tearing. Some of these events were similar to the underlying disease being studied.
Read the Emadine (emedastine difumarate ophthalmic solution) Side Effects Center for a complete guide to possible side effects
No information provided.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 11/7/2008
Additional Emadine Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Allergies & Asthma
Improve treatments & prevent attacks.